Author
WE. Evans / MV. Relling
Dr.Antonio Esteve Foundation
TORRE ESTEVEPasseig de la Zona Franca, 109
08038 Barcelona
Tel:
93 433 53 20
E-mail:
fundacion@esteve.org
Author
WE. Evans / MV. Relling
Year of publication
2003
In its fifth volume, the Esteve Foundation Series Pharmacotherapy revisited has gathered the facsimile edited main articles published between 1980 and 2000 on cancer pharmacokinetics and pharmacogenetics. Edited by William E. Evans and Mary V. Relling, from the Department of Pharmaceutic Sciences of the Hospital St. Jude Children of Memphis, United States, this compilation gathers in one single publication some of the most important advances reached in the field of cancer research and cancer patient treatment.
Full document | ||
Full PDF | WE. Evans / MV. Relling | [wpdm type=”btn3″] |
Chapters | ||
Chapters | Acknowledgements | [wpdm id=27 type=”btn”] |
Introduction | WE. Evans / MV. Relling | [wpdm id=29 type=”btn”] |
Index | [wpdm id=28 type=”btn”] | |
1. Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function | MJ. Egorin / DA. Van Echo / SJ. Tipping / EA. Olman / MY. Whitacre / BW. Thompson / J. Aisner | [wpdm type=”btn3″] |
2. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect | WE. Evans / WR. Crom / M. Abromowitch / R. Dodge / AT. Look / WP. Bowman / SL. George / C-H. Pui | [wpdm type=”btn3″] |
3. Clinical pharmacodynamics of continuous infusion teniposide: Systemic exposure as a determinant of response in a phase I trial | JH. Rodman / M. Abromowitch / JA. Sinkule / FA. Hayes / GK. Rivera / WE. Evans | [wpdm type=”btn3″] |
4. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation | GC. Yee / SG. Self / TR. McGuire / J. Carlin / JE. Sanders / HJ. Deeg | [wpdm type=”btn3″] |
5. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity | RB. Diasio / TL. Beavers / JT. Carpenter | [wpdm type=”btn3″] |
6. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function | AH. Calvert / DR. Newell / LA. Gumbrell / S. O\’Reilly / M. Burnell / FE. Boxall / ZH. Siddik / IR. Judson / ME. Gore / E. Wiltshaw | [wpdm type=”btn3″] |
7. Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation | LB. Grochow / RJ. Jones / RB. Brundrett / HG. Braine / T-L. Chen / R. Saral / GW. Santos / OM. Colvin | [wpdm type=”btn3″] |
8. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia | L. Lennard / JS. Lilleyman / J. Van Loon / RM. Weinshilboum | [wpdm type=”btn3″] |
9. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia | WE. Evans / M. Horner / YQ. Chu / D. Kalwinsky / WM. Roberts | [wpdm type=”btn3″] |
10. Relation of systemic exposure to unbound etoposide and hematologic toxicity | CF. Stewart / SG. Arbuck / RA. Fleming / WE. Evans | [wpdm type=”btn3″] |
11. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer | DI. Jodrell / MJ. Egorin / RM. Canetta / P. Langenberg / EP. Goldbloom / JN. Burroughs / JL. Goodlow / S. Tan / E. Wiltshaw | [wpdm type=”btn3″] |
12. Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion | J-M. Extra / F. Rousseau / R. Bruno / M. Clavel / N. Le Bail / M. Marty | [wpdm type=”btn3″] |
13. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy | V. Gandhi / E. Estey / MJ. Keating / W. Plunkett | [wpdm type=”btn3″] |
14. Relationship between fluorouracil systemic exposure and tumor response and patient survival | G. Milano / MC. Etienne / N. Renée / A. Thyss / M. Schneider / A. Ramaioli / F. Demard | [wpdm type=”btn3″] |
15. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia | TW. Synold / MV. Relling / JM. Boyett / GK. Rivera / JT. Sandlund / H. Mahmoud / WM. Crist / C-H. Pui / WE. Evans | [wpdm type=”btn3″] |
16. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors | DS. Sonnichsen / CA. Hurwitz / CB. Pratt / JJ. Shuster / MV. Relling | [wpdm type=”btn3″] |
17. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans | L. Gianni / CM. Kearns / A. Giani / G. Capri / L. Viganó / A. Locatelli / G. Bonadonna / MJ. Egorin | [wpdm type=”btn3″] |
18. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance | CR. Yates / EY. Krynetski / T. Loennechen / MY. Fessing / H-L. Tai / C-H. Pui / MV. Relling / WE. Evans | [wpdm type=”btn3″] |
19. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation | JT. Slattery / RA. Clift / CD. Buckner / J. Radich / B. Storer / WI. Bensinger et al. | [wpdm type=”btn3″] |
20. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia | WE. Evans / MV. Relling / JH. Rodman / WR. Crom / JM. Boyett / C-H. Pui | [wpdm type=”btn3″] |
21. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes | L. Iyer / CD. King / PF. Whitington / MD. Green / SK. Roy / TR. Tephly / BL. Coffman / MJ. Ratain | [wpdm type=”btn3″] |
22. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus | MV. Relling / ML. Hancock / GK. Rivera / JT. Sandlund / RC. Ribeiro / EY. Krynetski / C-H. Pui / WE. Evans | [wpdm type=”btn3″] |